دورية أكاديمية
أعرض في EDS

Alvespimycin Exhibits Potential Anti-TGF-β Signaling in the Setting of a Proteasome Activator in Rats with Bleomycin-Induced Pulmonary Fibrosis: A Promising Novel Approach.

التفاصيل البيبلوغرافية
العنوان: Alvespimycin Exhibits Potential Anti-TGF-β Signaling in the Setting of a Proteasome Activator in Rats with Bleomycin-Induced Pulmonary Fibrosis: A Promising Novel Approach.
المؤلفون: Mohammed OA; Department of Clinical Pharmacology, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia., Abdel-Reheim MA; Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni Suef 62521, Egypt., Saleh LA; Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.; Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia., Alamri MMS; Department of Family Medicine, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia., Alfaifi J; Department of Child Health, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia., Adam MIE; Department of Medical Education and Internal Medicine, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia., Farrag AA; Department of Histology and Cell Biology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.; Unit of Anatomy, Department of Basic Medical Sciences, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia., AlQahtani AAJ; Department of Internal Medicine, Division of Dermatology, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia., BinAfif WF; Department of Internal Medicine, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia., Hashish AA; Department of Basic Medical Sciences, College of Medicine, University of Bisha, Bisha 61922, Saudi Arabia.; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt., Abdel-Ghany S; Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt., Elmorsy EA; Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.; Pharmacology and Therapeutics Department, Qassim College of Medicine, Qassim University, Buraydah 51452, Saudi Arabia., El-Wakeel HS; Physiology Department, Benha Faculty of Medicine, Benha University, Benha 13518, Egypt.; Physiology Department, Albaha Faculty of Medicine, Albaha University, Al Baha 65799, Saudi Arabia., Doghish AS; Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo, Cairo 11829, Egypt.; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11231, Egypt., Hamad RS; Biological Sciences Department, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia.; Central Laboratory, Theodor Bilharz Research Institute, Giza 12411, Egypt., Saber S; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.
المصدر: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2023 Aug 09; Vol. 16 (8). Date of Electronic Publication: 2023 Aug 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c2004-
مستخلص: Idiopathic pulmonary fibrosis (IPF) is an irreversible and life-threatening lung disease of unknown etiology presenting only a few treatment options. TGF-β signaling orchestrates a cascade of events driving pulmonary fibrosis (PF). Notably, recent research has affirmed the augmentation of TGF-β receptor (TβR) signaling via HSP90 activation. HSP90, a molecular chaperone, adeptly stabilizes and folds TβRs, thus intricately regulating TGF-β1 signaling. Our investigation illuminated the impact of alvespimycin, an HSP90 inhibitor, on TGF-β-mediated transcriptional responses by inducing destabilization of TβRs. This outcome stems from the explicit interaction of TβR subtypes I and II with HSP90, where they are clients of this cellular chaperone. It is worth noting that regulation of proteasome-dependent degradation of TβRs is a critical standpoint in the termination of TGF-β signal transduction. Oleuropein, the principal bioactive compound found in Olea europaea , is acknowledged for its role as a proteasome activator. In this study, our aim was to explore the efficacy of a combined therapy involving oleuropein and alvespimycin for the treatment of PF. We employed a PF rat model that was induced by intratracheal bleomycin infusion. The application of this dual therapy yielded a noteworthy impediment to the undesired activation of TGF-β/mothers against decapentaplegic homologs 2 and 3 (SMAD2/3) signaling. Consequently, this novel combination showcased improvements in both lung tissue structure and function while also effectively restraining key fibrosis markers such as PDGF-BB, TIMP-1, ACTA2, col1a1, and hydroxyproline. On a mechanistic level, our findings unveiled that the antifibrotic impact of this combination therapy likely stemmed from the enhanced degradation of both TβRI and TβRII. In conclusion, the utilization of proteasomal activators in conjunction with HSP90 inhibitors ushers in a promising frontier for the management of PF.
References: Biomed Pharmacother. 2023 Feb;158:114196. (PMID: 36916405)
Front Pharmacol. 2022 Jun 08;13:887233. (PMID: 35754464)
Biomed Pharmacother. 2022 Sep;153:113247. (PMID: 35724510)
Nutr Res Rev. 2005 Jun;18(1):98-112. (PMID: 19079898)
Acta Cir Bras. 2021 Feb 15;36(1):e360107. (PMID: 33605309)
J Mol Cell Cardiol. 2007 Mar;42(3):549-58. (PMID: 17223128)
Lab Invest. 2012 Nov;92(11):1583-96. (PMID: 22964853)
Biochem Pharmacol. 2010 Sep 15;80(6):920-31. (PMID: 20513440)
EMBO J. 2013 May 15;32(10):1409-24. (PMID: 23612611)
Environ Sci Pollut Res Int. 2022 Apr;29(17):25723-25732. (PMID: 34845640)
Cells. 2019 Dec 24;9(1):. (PMID: 31878360)
Med Res Rev. 2022 Jan;42(1):156-182. (PMID: 33846988)
Nat Rev Cancer. 2005 Oct;5(10):761-72. (PMID: 16175177)
Front Pharmacol. 2021 Aug 16;12:719984. (PMID: 34489707)
Cells. 2022 Jun 30;11(13):. (PMID: 35805179)
PLoS One. 2016 May 25;11(5):e0155583. (PMID: 27224288)
Rejuvenation Res. 2007 Jun;10(2):157-72. (PMID: 17518699)
Cell Res. 2009 Jan;19(1):8-20. (PMID: 19114991)
Cell Biosci. 2012 Mar 15;2:9. (PMID: 22420375)
Mol Cell Biochem. 2009 Oct;330(1-2):181-5. (PMID: 19412730)
PLoS One. 2011;6(11):e27296. (PMID: 22096546)
Cells. 2021 Aug 18;10(8):. (PMID: 34440889)
J Clin Pathol. 2013 Oct;66(10):896-903. (PMID: 23703852)
Int J Parasitol Drugs Drug Resist. 2018 Apr;8(1):104-111. (PMID: 29499568)
Am J Physiol Renal Physiol. 2008 Jul;295(1):F202-14. (PMID: 18417540)
Trends Biochem Sci. 2022 Dec;47(12):1059-1072. (PMID: 35810076)
Life Sci. 1998;62(6):541-6. (PMID: 9464466)
Am J Respir Crit Care Med. 2014 May 15;189(10):1161-72. (PMID: 24641682)
J Histochem Cytochem. 2016 Mar;64(3):157-67. (PMID: 26747705)
Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19. (PMID: 11855755)
Cell Signal. 2021 Aug;84:110001. (PMID: 33812911)
Cell Res. 2009 Feb;19(2):156-72. (PMID: 19153598)
Pharmacol Res. 2021 Jan;163:105316. (PMID: 33248198)
Exp Gerontol. 2005 Dec;40(12):931-8. (PMID: 16246514)
Lancet Respir Med. 2018 Feb;6(2):154-160. (PMID: 29413083)
Biomed Pharmacother. 2023 Aug;164:114918. (PMID: 37216705)
Eur Respir J. 2017 Feb 23;49(2):. (PMID: 28182573)
Am J Respir Cell Mol Biol. 2019 Jun;60(6):629-636. (PMID: 30543447)
Life Sci. 2021 Dec 1;286:120070. (PMID: 34688695)
Med Res Rev. 2002 Jan;22(1):65-75. (PMID: 11746176)
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9244-9. (PMID: 18591668)
Biomed Pharmacother. 2021 Mar;135:111067. (PMID: 33383375)
J Am Soc Mass Spectrom. 2006 Apr;17(4):568-75. (PMID: 16503156)
Biomed Pharmacother. 2022 Sep;153:113487. (PMID: 36076505)
Genes Dev. 2000 Mar 15;14(6):627-44. (PMID: 10733523)
J Nutr. 2006 Aug;136(8):2213-9. (PMID: 16857843)
Toxicol Appl Pharmacol. 2019 May 15;371:63-73. (PMID: 30953615)
Chem Biol Interact. 2016 May 25;252:54-60. (PMID: 27019295)
Biomed Pharmacother. 2022 Mar;147:112628. (PMID: 35032769)
Expert Opin Ther Targets. 2021 Jan;25(1):49-62. (PMID: 33287600)
Toxicol Appl Pharmacol. 2020 Aug 1;400:115075. (PMID: 32470352)
J Med Chem. 2010 Jun 24;53(12):4585-602. (PMID: 20334364)
Pharmacol Ther. 2021 Jun;222:107798. (PMID: 33359599)
Bioorg Med Chem. 2019 Nov 1;27(21):115080. (PMID: 31519378)
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):622-9. (PMID: 12615669)
Growth Factors. 2011 Oct;29(5):196-202. (PMID: 21740331)
Cell Signal. 2015 Dec;27(12):2410-24. (PMID: 26362850)
J Biol Chem. 2005 Jun 24;280(25):23727-34. (PMID: 15845543)
Int J Mol Sci. 2021 Jun 03;22(11):. (PMID: 34204949)
Lancet Oncol. 2000 Oct;1:107-12. (PMID: 11905662)
Biomed Pharmacother. 2022 Apr;148:112723. (PMID: 35202914)
Food Funct. 2017 Oct 18;8(10):3737-3744. (PMID: 28952621)
Am J Respir Crit Care Med. 2020 Mar 1;201(5):564-574. (PMID: 31710517)
Curr Med Chem. 2009;16(8):931-9. (PMID: 19275603)
J Clin Invest. 2018 Jan 2;128(1):45-53. (PMID: 29293088)
فهرسة مساهمة: Keywords: HSP90/TGF-β; TβR; alvespimycin (17-DMAG); bleomycin-induced pulmonary fibrosis; oleuropein; proteasome
تواريخ الأحداث: Date Created: 20230826 Latest Revision: 20230829
رمز التحديث: 20230830
مُعرف محوري في PubMed: PMC10458542
DOI: 10.3390/ph16081123
PMID: 37631038
قاعدة البيانات: MEDLINE
الوصف
تدمد:1424-8247
DOI:10.3390/ph16081123